Disclosures for "SB12, Biosimilar To Eculizumab (Complement 5 Inhibitor) For Generalized Myasthenia Gravis "
-
Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Samsung Bioepis. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for J&J. The institution of Dr. Kang has received research support from UCSF resource allocation program .
-
Dr. Baek has received personal compensation for serving as an employee of Samsung Bioepis Co., Ltd.
-
Dr. Jung has received personal compensation for serving as an employee of Samsung Bioepis Co., Ltd..
-
Mr. KIM has received personal compensation for serving as an employee of Samsung Bioepis Co., Ltd..